

7 Literaturverzeichnis

- Abruzzese, R. V., Godin, D., Burcin, M., Mehta, V., French, M., Li, Y., O'Malley, B. W., and Nordstrom, J. L. (1999) Ligand-dependent regulation of plasmid-based transgene expression in vivo. *Hum Gene Ther* **10**, 1499-1507.
- Adami, G. and Nevins, J. R. (1988) Splice site selection dominates over poly(A) site choice in RNA production from complex adenovirus transcription units. *EMBO J* **7**, 2107-2116.
- Agha-Mohammadi, S., O'Malley, M., Etemad, A., Wang, Z., Xiao, X., and Lotze, M. T. (2004) Second-generation tetracycline-regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakiness. *J Gene Med* **6**, 817-828.
- Aleman, R., Balague, C., and Curiel, D. T. (2000a) Replicative adenoviruses for cancer therapy. *Nat Biotechnol* **18**, 723-727.
- Aleman, R., Suzuki, K., and Curiel, D. T. (2000b) Blood clearance rates of adenovirus type 5 in mice. *J Gen Virol* **81**, 2605-2609.
- Algeciras-Schimmich, A., Pietras, E. M., Barnhart, B. C., Legembre, P., Vijayan, S., Holbeck, S. L., and Peter, M. E. (2003) Two CD95 tumor classes with different sensitivities to antitumor drugs. *Proc Natl Acad Sci U S A* **100**, 11445-11450.
- Amalfitano, A., Hauser, M. A., Hu, H., Serra, D., Begy, C. R., and Chamberlain, J. S. (1998) Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. *J Virol* **72**, 926-933.
- Arai, H., Gordon, D., Nabel, E. G., and Nabel, G. J. (1997) Gene transfer of Fas ligand induces tumor regression in vivo. *Proc Natl Acad Sci U S A* **94**, 13862-13867.
- Arany, Z., Newsome, D., Oldread, E., Livingston, D. M., and Eckner, R. (1995) A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. *Nature* **374**, 81-84.
- Arrand, J. R. and Roberts, R. J. (1979) The nucleotide sequences at the termini of adenovirus-2 DNA. *J Mol Biol* **128**, 577-594.
- Ashkenazi, A. and Dixit, V. M. (1998) Death receptors: signaling and modulation. *Science* **281**, 1305-1308.
- Auricchio, L., Bujard, H., Hillen, W., Cortese, R., Ciliberto, G., La Monica, N., and Palombo, F. (2001) Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector. *Gene Ther* **8**, 1817-1825.
- Avvakumov, N. and Mymryk, J. S. (2002) New tools for the construction of replication-competent adenoviral vectors with altered E1A regulation. *J Virol Methods* **103**, 41-49.
- Bailey, A. and Mautner, V. (1994) Phylogenetic relationships among adenovirus serotypes. *Virology* **205**, 438-452.

- Balague, C., Noya, F., Alemany, R., Chow, L. T., and Curiel, D. T. (2001) Human papillomavirus E6E7-mediated adenovirus cell killing: selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. *J Virol* **75**, 7602-7611.
- Bateman, A., Bullough, F., Murphy, S., Emiliusen, L., Lavillette, D., Cosset, F. L., Cattaneo, R., Russell, S. J., and Vile, R. G. (2000) Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. *Cancer Res* **60**, 1492-1497.
- Beltinger, C., Fulda, S., Kammertoens, T., Meyer, E., Uckert, W., and Debatin, K. M. (1999) Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. *Proc Natl Acad Sci U S A* **96**, 8699-8704.
- Bennett, E. M., Bennink, J. R., Yewdell, J. W., and Brodsky, F. M. (1999) Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. *J Immunol* **162**, 5049-5052.
- Bergelson, J. M. (1999) Receptors mediating adenovirus attachment and internalization. *Biochem Pharmacol* **57**, 975-979.
- Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., and Finberg, R. W. (1997) Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* **275**, 1320-1323.
- Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. *Science* **274**, 373-376.
- Bohinski, R. J., Huffman, J. A., Whitsett, J. A., and Lattier, D. L. (1993) Cis-active elements controlling lung cell-specific expression of human pulmonary surfactant protein B gene. *J Biol Chem* **268**, 11160-11166.
- Boyer, J., Rohleder, K., and Ketner, G. (1999) Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. *Virology* **263**, 307-312.
- Brown, J. R. and DuBois, R. N. (2004) Cyclooxygenase as a Target in Lung Cancer. *Clin Cancer Res* **10**, 4266S-44269.
- Brunori, M., Malerba, M., Kashiwazaki, H., and Iggo, R. (2001) Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway. *J Virol* **75**, 2857-2865.
- Bullani, R. R., Wehrli, P., Viard-Leveugle, I., Rimoldi, D., Cerottini, J. C., Saurat, J. H., Tschopp, J., and French, L. E. (2002) Frequent downregulation of Fas (CD95) expression and function in melanoma. *Melanoma Res* **12**, 263-270.

- Caplen, N. J., Higginbotham, J. N., Scheel, J. R., Vahanian, N., Yoshida, Y., Hamada, H., Blaese, R. M., and Ramsey, W. J. (1999) Adeno-retroviral chimeric viruses as in vivo transducing agents. *Gene Ther* **6**, 454-459.
- Cheng, J., Zhou, T., Liu, C., Shapiro, J. P., Brauer, M. J., Kiefer, M. C., Barr, P. J., and Mountz, J. D. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. *Science* **263**, 1759-1762.
- Chong, H., Ruchatz, A., Clackson, T., Rivera, V. M., and Vile, R. G. (2002) A system for small-molecule control of conditionally replication-competent adenoviral vectors. *Mol Ther* **5**, 195-203.
- Chroboczek, J., Bieber, F., and Jacrot, B. (1992) The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. *Virology* **186**, 280-285.
- Chu, R. L., Post, D. E., Khuri, F. R., and Van Meir, E. G. (2004) Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer. *Clin Cancer Res* **10**, 5299-5312.
- Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. (2000) Genomic analysis of metastasis reveals an essential role for RhoC. *Nature* **406**, 532-535.
- Cuevas, Y., Hernandez-Alcoceba, R., Aragonés, J., Naranjo-Suarez, S., Castellanos, M. C., Esteban, M. A., Martín-Puig, S., Landazuri, M. O., and del Peso, L. (2003) Specific Oncolytic Effect of a New Hypoxia-Inducible Factor-Dependent Replicative Adenovirus on von Hippel-Lindau-Defective Renal Cell Carcinomas. *Cancer Res* **63**, 6877-6884.
- Curiel, D. T. (2000) The development of conditionally replicative adenoviruses for cancer therapy. *Clin Cancer Res* **6**, 3395-3399.
- Curtis, S., Wilkinson, G. W., and Westmoreland, D. (1998) An outbreak of epidemic keratoconjunctivitis caused by adenovirus type 37. *J Med Microbiol* **47**, 91-94.
- D'Halluin, J. C. (1995) Virus assembly. *Curr Top Microbiol Immunol* **199**, 47-66.
- Danthinne, X. and Imperiale, M. J. (2000) Production of first generation adenovirus vectors: a review. *Gene Ther* **7**, 1707-1714.
- de Jong, R. N., Meijer, L. A., and van der Vliet, P. C. (2003) DNA binding properties of the adenovirus DNA replication priming protein pTP. *Nucleic Acids Res* **31**, 3274-3286.
- Dery, C. V., Toth, M., Brown, M., Horvath, J., Allaire, S., and Weber, J. M. (1985) The structure of adenovirus chromatin in infected cells. *J Gen Virol* **66**, 2671-2684.
- Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A. E., Krajcsi, P., Krougliak, V., and Wold, W. S. (2001) Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. *J Virol* **75**, 3314-3324.
- Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., and Wold, W. S. (2000) Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein [In Process Citation]. *J Virol* **74**, 6147-6155.

- Eberle, J., Fecker, L. F., Hossini, A. M., Wieder, T., Daniel, P. T., Orfanos, C. E., and Geilen, C. C. (2003) CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. *Oncogene* **22**, 9131-9141.
- Eiz, B. and Pring-Akerblom, P. (1997) Molecular characterization of the type-specific gamma-determinant located on the adenovirus fiber. *J Virol* **71**, 6576-6581.
- Enari, M., Sakahira, H., Yokoyama, H., Okawa, K., Iwamatsu, A., and Nagata, S. (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature* **391**, 43-50.
- Faulk, W. P., Harats, H., McIntyre, J. A., Berczi, A., Sun, I. L., and Crane, F. L. (1989) Recent advances in cancer research: drug targeting without the use of monoclonal antibodies. *Am J Reprod Immunol* **21**, 151-154.
- Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., Schoemaker, R., Veghel, R., Houtsmuller, A., Schultheiss, H. P., Lamers, J., and Poller, W. (1999) Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. *Gene Ther* **6**, 1520-1535.
- Fechner, H., Wang, X., Srour, M., Siemetzki, U., Seltmann, H., Sutter, A. P., Scherubl, H., Zouboulis, C. C., Schwaab, R., Hillen, W., Schultheiss, H. P., and Poller, W. (2003a) A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. *Gene Ther* **10**, 1680-1690.
- Fechner, H., Wang, X., Wang, H., Jansen, A., Pauschinger, M., Scherubl, H., Bergelson, J. M., Schultheiss, H. P., and Poller, W. (2000) Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. *Gene Ther* **7**, 1954-1968.
- Fechner, H., Noutsias, M., Tschoepe, C., Hinze, K., Wang, X., Escher, F., Pauschinger, M., Dekkers, D., Vetter, R., Paul, M., Lamers, J., Schultheiss, H. P., and Poller, W. (2003b) Induction of Coxsackievirus-Adenovirus-Receptor Expression During Myocardial Tissue Formation and Remodeling: Identification of a Cell-to-Cell Contact-Dependent Regulatory Mechanism. *Circulation* **107**, 876-882.
- Flotte, T. R. (1993) Prospects for virus-based gene therapy for cystic fibrosis. *J Bioenerg Biomembr* **25**, 37-42.
- Freundlieb, S., Baron, U., Bonin, A. L., Gossen, M., and Bujard, H. (1997) Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. *Methods Enzymol* **283:159-73**, 159-173.

- Freundlieb, S., Schirra-Muller, C., and Bujard, H. (1999) A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. *J Gene Med* **1**, 4-12.
- Fuerer, C. and Iggo, R. (2002) Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. *Gene Ther* **9**, 270-281.
- Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K., and Kyritsis, A. P. (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. *Oncogene* **19**, 2-12.
- Fulda, S., Los, M., Friesen, C., and Debatin, K. M. (1998) Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. *Int J Cancer* **76**, 105-114.
- Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. (1997) The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. *Cancer Res* **57**, 3823-3829.
- Fussenegger, M., Morris, R. P., Fux, C., Rimann, M., von Stockar, B., Thompson, C. J., and Bailey, J. E. (2000) Streptogramin-based gene regulation systems for mammalian cells. *Nat Biotechnol* **18**, 1203-1208.
- Galle, P. R. and Krammer, P. H. (1998) CD95-induced apoptosis in human liver disease. *Semin Liver Dis* **18**, 141-151.
- Ganly, I., Kim, D., Eckhardt, S. G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., and Kaye, S. B. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. *Clin Cancer Res* **6**, 798-806.
- Ganly, I. and Singh, B. (2003) Topical ONYX-015 in the treatment of premalignant oral dysplasia: another role for the cold virus? *J Clin Oncol* **21**, 4476-4478.
- Gaynor, R. B., Hillman, D., and Berk, A. J. (1984) Adenovirus early region 1A protein activates transcription of a nonviral gene introduced into mammalian cells by infection or transfection. *Proc Natl Acad Sci U S A* **81**, 1193-1197.
- Goldsmith, K. T., Dion, L. D., Curiel, D. T., and Garver, R. I. J. (1998) trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus. *Virology* **248**, 406-419.
- Gomez-Navarro, J., Curiel, D. T., and Douglas, J. T. (1999) Gene therapy for cancer. *Eur J Cancer* **35**, 2039-2057.
- Gooding, L. R., Sofola, I. O., Tollefson, A. E., Duerksen-Hughes, P., and Wold, W. S. (1990) The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. *J Immunol* **145**, 3080-3086.

- Goodrum, F. D. and Ornelles, D. A. (1998) p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. *J Virol* **72**, 9479-9490.
- Gossen, M. and Bujard, H. (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. *Proc Natl Acad Sci U S A* **89**, 5547-5551.
- Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995) Transcriptional activation by tetracyclines in mammalian cells. *Science* **268**, 1766-1769.
- Grable, M. and Hearing, P. (1990) Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. *J Virol* **64**, 2047-2056.
- Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J Gen Virol* **36**, 59-74.
- Greber, U. F., Webster, P., Weber, J., and Helenius, A. (1996) The role of the adenovirus protease on virus entry into cells. *EMBO J* **15**, 1766-1777.
- Greber, U. F., Willetts, M., Webster, P., and Helenius, A. (1993) Stepwise dismantling of adenovirus 2 during entry into cells. *Cell* **75**, 477-486.
- Green, A. P., Huang, J. J., Scott, M. O., Kierstead, T. D., Beaupre, I., Gao, G. P., and Wilson, J. M. (2002) A new scalable method for the purification of recombinant adenovirus vectors. *Hum Gene Ther* **13**, 1921-1934.
- Gu, J., Kagawa, S., Takakura, M., Kyo, S., Inoue, M., Roth, J. A., and Fang, B. (2000) Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. *Cancer Res* **60**, 5359-5364.
- Haack, A., Poller, W., Schneider-Rasp, S., Thalheimer, P., Schmitt, C., Hanfland, P., Brackmann, H. H., and Schwaab, R. (1999) Highly sensitive and species-specific assay for quantification of human transgene expression levels. *Haemophilia* **5**, 334-339.
- Hackett N.R. and Crystal R.G. (2000) Adenoviral vectors for gene therapy. In: *Gene therapy: therapeutic mechanisms and strategies*, pp. 17-59. Eds Templeton N.S., Lasic D.D. Marcel Dekker, Inc.: New York, Basel.
- Hahne, M., Rimoldi, D., Schroter, M., Romero, P., Schreier, M., French, L. E., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J., and Tschopp, J. (1996) Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. *Science* **274**, 1363-1366.
- Halbert, D. N., Cutt, J. R., and Shenk, T. (1985) Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. *J Virol* **56**, 250-257.
- Hallenbeck, P. L., Chang, Y. N., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y. L. (1999) A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. *Hum Gene Ther* **10**, 1721-1733.

- Harui, A., Suzuki, S., Kochanek, S., and Mitani, K. (1999) Frequency and stability of chromosomal integration of adenovirus vectors. *J Virol* **73**, 6141-6146.
- Harvey, D. M. and Caskey, C. T. (1998) Inducible control of gene expression: prospects for gene therapy. *Curr Opin Chem Biol* **2**, 512-518.
- Haviv, Y. S. and Curiel, D. T. (2001) Conditional gene targeting for cancer gene therapy. *Adv Drug Deliv Rev* **53**, 135-154.
- Hay, R. T., Freeman, A., Leith, I., Monaghan, A., and Webster, A. (1995) Molecular interactions during adenovirus DNA replication. *Curr Top Microbiol Immunol* **199**, 31-48.
- Hearing, P. and Shenk, T. (1986) The adenovirus type 5 E1A enhancer contains two functionally distinct domains: one is specific for E1A and the other modulates all early units in cis. *Cell* **45**, 229-236.
- Hedlund, T. E., Meech, S. J., Srikanth, S., Kraft, A. S., Miller, G. J., Schaack, J. B., and Duke, R. C. (1999) Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. *Cell Death Differ* **6**, 175-182.
- Heidenreich, R., Kappel, A., and Breier, G. (2000) Tumor endothelium-specific transgene expression directed by vascular endothelial growth factor receptor-2 (Flk-1) promoter/enhancer sequences. *Cancer Res* **60**, 6142-6147.
- Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy [In Process Citation]. *Nat Med* **6**, 1134-1139.
- Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents [see comments]. *Nat Med* **3**, 639-645.
- Henriksen, R., Gobl, A., Wilander, E., Oberg, K., Miyazono, K., and Funa, K. (1995) Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. *Lab Invest* **73**, 213-220.
- Hernandez-Alcoceba, R., Pihalja, M., Qian, D., and Clarke, M. F. (2002) New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. *Hum Gene Ther* **20;13**, 1737-1750.
- Hernandez-Alcoceba, R., Pihalja, M., Wicha, M. S., and Clarke, M. F. (2000) A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors [In Process Citation]. *Hum Gene Ther* **11**, 2009-2024.
- Hierholzer, J. C. (1973) Further subgrouping of the human adenoviruses by differential hemagglutination. *J Infect Dis* **128**, 541-550.

- Hitt, M. M. and Graham, F. L. (1990) Adenovirus E1A under the control of heterologous promoters: wide variation in E1A expression levels has little effect on virus replication. *Virology* **179**, 667-678.
- Hitt, M. M. and Graham, F. L. (2000) Adenovirus vectors for human gene therapy. *Adv Virus Res* **55**, 479-505.
- Horwitz, M. S. (1996) In: *Fields Virology*, pp. 2149. Ed K. D. H. P. Fields BN. Lippincott-Raven: Philadelphia, New York.
- Hsieh, C. L., Yang, L., Miao, L., Yeung, F., Kao, C., Yang, H., Zhau, H. E., and Chung, L. W. K. (2002) A Novel Targeting Modality to Enhance Adenoviral Replication by Vitamin D3 in Androgen-independent Human Prostate Cancer Cells and Tumors. *Cancer Res* **62**, 3084-3092.
- Hu, S. X., Ji, W., Zhou, Y., Logothetis, C., and Xu, H. J. (1997) Development of an adenovirus vector with tetracycline-regulatable human tumor necrosis factor alpha gene expression. *Cancer Res* **57**, 3339-3343.
- Huang, T. G., Savontaus, M. J., Shinozaki, K., Sauter, B. V., and Woo, S. L. (2003) Telomerase-dependent oncolytic adenovirus for cancer treatment. *Gene Ther* **10**, 1241-1247.
- Igney, F. H., Behrens, C. K., and Krammer, P. H. (2003) The influence of CD95L expression on tumor rejection in mice. *Eur J Immunol* **33**, 2811-2821.
- Imhof, M. O., Chatellard, P., and Mermod, N. (2000) A regulatory network for the efficient control of transgene expression. *J Gene Med* **2**, 107-116.
- Imperiale, M. J. and Kochanek, S. (2004) Adenovirus vectors: biology, design, and production. *Curr Top Microbiol Immunol* **273**, 335-357.
- Irmeler, M., Thome, M., Hahne, M., Schneider, P., Hofmann, K., Steiner, V., Bodmer, J. L., Schroter, M., Burns, K., Mattmann, C., Rimoldi, D., French, L. E., and Tschopp, J. (1997) Inhibition of death receptor signals by cellular FLIP. *Nature* **388**, 190-195.
- Jager, U., Zhao, Y., and Porter, C. D. (1999) Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. *J Virol* **73**, 9702-9709.
- Jaggar, R. T., Chan, H. Y., Harris, A. L., and Bicknell, R. (1997) Endothelial cell-specific expression of tumor necrosis factor-alpha from the KDR or E-selectin promoters following retroviral delivery. *Hum Gene Ther* **8**, 2239-2247.
- Jiang, S., Song, M. J., Shin, E. C., Lee, M. O., Kim, S. J., and Park, J. H. (1999) Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. *Hepatology* **29**, 101-110.

- Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., McCormick, F., and Fattaey, A. (2002) Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. *Cancer Cell* **1**, 325-337.
- Joki, T., Nakamura, M., and Ohno, T. (1995) Activation of the radiosensitive EGR-1 promoter induces expression of the herpes simplex virus thymidine kinase gene and sensitivity of human glioma cells to ganciclovir. *Hum Gene Ther* **6**, 1507-1513.
- Kafri, T., van Praag, H., Gage, F. H., and Verma, I. M. (2000) Lentiviral vectors: regulated gene expression. *Mol Ther* **1**, 516-521.
- Kanai, F., Lan, K. H., Shiratori, Y., Tanaka, T., Ohashi, M., Okudaira, T., Yoshida, Y., Wakimoto, H., Hamada, H., Nakabayashi, H., Tamaoki, T., and Omata, M. (1997) In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. *Cancer Res* **57**, 461-465.
- Kanerva, A. and Hemminki, A. (2005) Adenoviruses for treatment of cancer. *Ann Med* **37**, 33-43.
- Katabi, M. M., Chan, H. L., Karp, S. E., and Batist, G. (1999) Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. *Hum Gene Ther* **10**, 155-164.
- Kaufman, R. J. (1985) Identification of the components necessary for adenovirus translational control and their utilization in cDNA expression vectors. *Proc Natl Acad Sci U S A* **82**, 689-693.
- Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. (1993) Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. *Cancer Res* **53**, 3976-3985.
- Kawasaki, M., Kuwano, K., Nakanishi, Y., Hagimoto, N., Takayama, K., Pei, X. H., Maeyama, T., Yoshimi, M., and Hara, N. (2000) Analysis of Fas and Fas ligand expression and function in lung cancer cell lines. *Eur J Cancer* **36**, 656-663.
- Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K., and Yagita, H. (1995) Metalloproteinase-mediated release of human Fas ligand. *J Exp Med* **182**, 1777-1783.
- Kebulusek, P., Dorsman, J. C., Teunisse, A. F., Teunissen, H., van der Eb, A. J., and Zantema, A. (1999) The adenoviral E1A oncoproteins interfere with the growth-inhibiting effect of the cdk-inhibitor p21(CIP1/WAF1). *J Gen Virol* **80**, 381-390.
- Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Brusio, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. (2000) a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [see comments]. *Nat Med* **6**, 879-885.

- Kirn, D. H. and McCormick, F. (1996) Replicating viruses as selective cancer therapeutics. *Mol Med Today* **2**, 519-527.
- Kischkel, F. C., Hellbardt, S., Behrmann, I., Germer, M., Pawlita, M., Krammer, P. H., and Peter, M. E. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. *EMBO J* **14**, 5579-5588.
- Koch, P., Gatfield, J., Lober, C., Hobom, U., Lenz-Stoppler, C., Roth, J., and Dobbelstein, M. (2001) Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. *Cancer Res* **61**, 5941-5947.
- Kochanek, S. (1999) High-capacity adenoviral vectors for gene transfer and somatic gene therapy. *Hum Gene Ther* **10**, 2451-2459.
- Koshikawa, N., Takenaga, K., Tagawa, M., and Sakiyama, S. (2000) Therapeutic efficacy of the suicide gene driven by the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. *Cancer Res* **60**, 2936-2941.
- Kringstein, A. M., Rossi, F. M., Hofmann, A., and Blau, H. M. (1998) Graded transcriptional response to different concentrations of a single transactivator. *Proc Natl Acad Sci U S A* **95**, 13670-13675.
- Kubo, S. and Mitani, K. (2003) A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. *J Virol* **77**, 2964-2971.
- Kumar, S., Ghellal, A., Li, C., Byrne, G., Haboubi, N., Wang, J. M., and Bundred, N. (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. *Cancer Res* **59**, 856-861.
- Lai, C. M., Lai, Y. K., and Rakoczy, P. E. (2002) Adenovirus and adeno-associated virus vectors. *DNA Cell Biol* **21**, 895-913.
- Lamartina, S., Roscilli, G., Rinaudo, C. D., Sporeno, E., Silvi, L., Hillen, W., Bujard, H., Cortese, R., Ciliberto, G., and Toniatti, C. (2002) Stringent control of gene expression in vivo by using novel doxycycline-dependent trans-activators. *Hum Gene Ther* **13**, 199-210.
- Lanson, N. A., Jr., Friedlander, P. L., Schwarzenberger, P., Kolls, J. K., and Wang, G. (2003) Replication of an Adenoviral Vector Controlled by the Human Telomerase Reverse Transcriptase Promoter Causes Tumor-Selective Tumor Lysis. *Cancer Res* **63**, 7936-7941.
- Leong, K., Lee, W., and Berk, A. J. (1990) High-level transcription from the adenovirus major late promoter requires downstream binding sites for late-phase-specific factors. *J Virol* **64**, 51-60.
- Li, C., Guo, B., Wilson, P. B., Stewart, A., Byrne, G., Bundred, N., and Kumar, S. (2000) Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. *Int J Cancer* **89**, 122-126.

- Li, Y., Chen, Y., Dilley, J., Arroyo, T., Ko, D., Working, P., and Yu, D. C. (2003) Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. *Mol Cancer Ther* **2**, 1003-1009.
- Li, Y., Yu, D. C., Chen, Y., Amin, P., Zhang, H., Nguyen, N., and Henderson, D. R. (2001) A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. *Cancer Res* **61**, 6428-6436.
- Lieber, A., Steinwaerder, D. S., Carlson, C. A., and Kay, M. A. (1999) Integrating adenovirus- adeno-associated virus hybrid vectors devoid of all viral genes. *J Virol* **73**, 9314-9324.
- Lillehammer, T., Tveito, S., Engesaeter, B. O., Fodstad, O., Maelandsmo, G. M., and Engebraaten, O. (2005) Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers. *Cancer Gene Ther* **12**, 864-872.
- Liu, X. Y., Gu, J. F., and Shi, W. F. (2005) Targeting gene-virotherapy for cancer. *Acta Biochim Biophys Sin (Shanghai)* **37**, 581-587.
- Majno, G. and Joris, I. (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* **146**, 3-15.
- Mariani, S. M., Matiba, B., Baumler, C., and Krammer, P. H. (1995) Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. *Eur J Immunol* **25**, 2303-2307.
- Martin, A. B., Webber, S., Fricker, F. J., Jaffe, R., Demmler, G., Kearney, D., Zhang, Y. H., Bodurtha, J., Gelb, B., and Ni, J. (1994) Acute myocarditis. Rapid diagnosis by PCR in children. *Circulation* **90**, 330-339.
- Matsubara, S., Wada, Y., Gardner, T. A., Egawa, M., Park, M. S., Hsieh, C. L., Zhau, H. E., Kao, C., Kamidono, S., Gillenwater, J. Y., and Chung, L. W. (2001) A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. *Cancer Res* **61**, 6012-6019.
- McCart, J. A., Wang, Z. H., Xu, H., Hu, Y., Park, B., Alexander, H. R., and Bartlett, D. L. (2002) Development of a melanoma-specific adenovirus. *Mol Ther* **6**, 471-480.
- Mei, Y. F. and Wadell, G. (1996) Epitopes and hemagglutination binding domain on subgenus B:2 adenovirus fibers. *J Virol* **70**, 3688-3697.
- Melcher, A., Todryk, S., Hardwick, N., Ford, M., Jacobson, M., and Vile, R. G. (1998) Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression. *Nat Med* **4**, 581-587.
- Miller, N. and Whelan, J. (1997) Progress in transcriptionally targeted and regulatable vectors for genetic therapy. *Hum Gene Ther* **8**, 803-815.

- Mizuguchi, H., Xu, Z. L., Sakurai, F., Mayumi, T., and Hayakawa, T. (2003) Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. *Hum Gene Ther* **14**, 1265-1277.
- Morimoto, E., Inase, N., Mlyake, S., and Yoshizawa, Y. (2001) Adenovirus-mediated suicide gene transfer to small cell lung carcinoma using a tumor-specific promoter. *Anticancer Res* **21**, 329-331.
- Morin, N. and Boulanger, P. (1984) Morphogenesis of human adenovirus type 2: sequence of entry of proteins into previral and viral particles. *Virology* **136**, 153-167.
- Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. (1997) Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. *J Clin Invest* **99**, 403-413.
- Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. (1998) p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. *J Exp Med* **188**, 2033-2045.
- Muruve, D. A., Cotter, M. J., Zaiss, A. K., White, L. R., Liu, Q., Chan, T., Clark, S. A., Ross, P. J., Meulenbroek, R. A., Maelandsmo, G. M., and Parks, R. J. (2004) Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. *J Virol* **78**, 5966-5972.
- Muschen, M., Moers, C., Warskulat, U., Even, J., Niederacher, D., and Beckmann, M. W. (2000a) CD95 ligand expression as a mechanism of immune escape in breast cancer. *Immunology* **99**, 69-77.
- Muschen, M., Warskulat, U., and Beckmann, M. W. (2000b) Defining CD95 as a tumor suppressor gene. *J Mol Med* **78**, 312-325.
- Nagata, S. (1997) Apoptosis by death factor. *Cell* **88**, 355-365.
- Nakanishi, H., Mazda, O., Satoh, E., Asada, H., Morioka, H., Kishida, T., Nakao, M., Mizutani, Y., Kawachi, A., Kita, M., Imanishi, J., and Miki, T. (2003) Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. *Gene Ther* **10**, 434-442.
- Nambu, Y., Hughes, S. J., Rehemtulla, A., Hamstra, D., Orringer, M. B., and Beer, D. G. (1998) Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. *J Clin Invest* **101**, 1102-1110.
- Nemerow, G. R. (2000) Cell receptors involved in adenovirus entry. *Virology* **274**, 1-4.
- Nemerow, G. R. and Stewart, P. L. (1999) Role of alpha(v) integrins in adenovirus cell entry and gene delivery. *Microbiol Mol Biol Rev* **63**, 725-734.

- Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. *Gene Ther* **8**, 746-759.
- Nemunaitis, J. and Edelman, J. (2002) Selectively replicating viral vectors. *Cancer Gene Ther* **9**, 987-1000.
- Nettelbeck, D. M. (2003) Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. *Anticancer Drugs* **14**, 577-584.
- Nettelbeck, D. M., Jerome, V., and Muller, R. (2000) Gene therapy: designer promoters for tumour targeting. *Trends Genet* **16**, 174-181.
- Nettelbeck, D. M., Rivera, A. A., Balague, C., Alemany, R., and Curiel, D. T. (2002) Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. *Cancer Res* **62**, 4663-4670.
- Newton, R., Seybold, J., Kuitert, L. M., Bergmann, M., and Barnes, P. J. (1998) Repression of cyclooxygenase-2 and prostaglandin E2 release by dexamethasone occurs by transcriptional and post-transcriptional mechanisms involving loss of polyadenylated mRNA. *J Biol Chem* **273**, 32312-32321.
- No, D., Yao, T. P., and Evans, R. M. (1996) Ecdysone-inducible gene expression in mammalian cells and transgenic mice. *Proc Natl Acad Sci U S A* **93**, 3346-3351.
- O'Connell, J., Bennett, M. W., O'Sullivan, G. C., Collins, J. K., and Shanahan, F. (1999) Fas counter-attack--the best form of tumor defense? *Nat Med* **5**, 267-268.
- O'Rourke, J. F., Dachs, G. U., Gleadle, J. M., Maxwell, P. H., Pugh, C. W., Stratford, I. J., Wood, S. M., and Ratcliffe, P. J. (1997) Hypoxia response elements. *Oncol Res* **9**, 327-332.
- Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T., and Nagata, S. (1993) Lethal effect of the anti-Fas antibody in mice. *Nature* **364**, 806-809.
- Ohashi, M., Kanai, F., Tateishi, K., Taniguchi, H., Marignani, P. A., Yoshida, Y., Shiratori, Y., Hamada, H., and Omata, M. (2001) Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. *Biochem Biophys Res Commun* **282**, 529-535.
- Ostapchuk, P. and Hearing, P. (2003) Minimal cis-acting elements required for adenovirus genome packaging. *J Virol* **77**, 5127-5135.
- Pauschinger, M., Doerner, A., Kuehl, U., Schwimmbeck, P. L., Poller, W., Kandolf, R., and Schultheiss, H. P. (1999) Enteroviral RNA Replication in the Myocardium of Patients With Left Ventricular Dysfunction and Clinically Suspected Myocarditis. *Circulation* **99**, 889-895.

- Pengue, G. and Lania, L. (1996) Kruppel-associated box-mediated repression of RNA polymerase II promoters is influenced by the arrangement of basal promoter elements. *Proc Natl Acad Sci U S A* **93**, 1015-1020.
- Poller, W., Schneider-Rasp, S., Liebert, U., Merklein, F., Thalheimer, P., Haack, A., Schwaab, R., Schmitt, C., and Brackmann, H. H. (1996) Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. *Gene Ther* **3**, 521-530.
- Post, D. E., Khuri, F. R., Simons, J. W., and Van Meir, E. G. (2003) Replicative oncolytic adenoviruses in multimodal cancer regimens. *Hum Gene Ther* **14**, 933-946.
- Post, D. E. and Van Meir, E. G. (2003) A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. *Oncogene* **22**, 2065-2072.
- Recchia, A., Parks, R. J., Lamartina, S., Toniatti, C., Pieroni, L., Palombo, F., Ciliberto, G., Graham, F. L., Cortese, R., La Monica, N., and Colloca, S. (1999) Site-specific integration mediated by a hybrid adenovirus/adenovirus-associated virus vector. *Proc Natl Acad Sci U S A* **96**, 2615-2620.
- Reichmann, E. (2002) The biological role of the Fas/FasL system during tumor formation and progression. *Semin Cancer Biol* **12**, 309-315.
- Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., and Kirn, D. (2002a) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res* **62**, 6070-6079.
- Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., and Kirn, D. (2002b) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res* **62**, 6070-6079.
- Rhoades, K. L., Golub, S. H., and Economou, J. S. (1996) The adenoviral transcription factor, E1A 13S, trans-activates the human tumor necrosis factor-alpha promoter. *Virus Res* **40**, 65-74.
- Richards, C. A., Austin, E. A., and Huber, B. E. (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. *Hum Gene Ther* **6**, 881-893.
- Ring, C. J. (2002) Cytolytic viruses as potential anti-cancer agents. *J Gen Virol* **83**, 491-502.
- Rivera, V. M., Clackson, T., Natesan, S., Pollock, R., Amara, J. F., Keenan, T., Magari, S. R., Phillips, T., Courage, N. L., Cerasoli, F., Jr., Holt, D. A., and Gilman, M. (1996) A humanized system for pharmacologic control of gene expression. *Nat Med* **2**, 1028-1032.
- Rodriguez, R., Schuur, E. R., Lim, H. Y., Henderson, G. A., Simons, J. W., and Henderson, D. R. (1997) Prostate attenuated replication competent adenovirus (ARCA) CN706: a

- selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. *Cancer Res* **57**, 2559-2563.
- Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., and Kirn, D. H. (2000) In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. *Cancer Res* **60**, 1193-1196.
- Rosa-Calatrava, M., Grave, L., Puvion-Dutilleul, F., Chatton, B., and Kedinger, C. (2001) Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. *J Virol* **75**, 7131-7141.
- Rossi, F. M., Guicherit, O. M., Spicher, A., Kringstein, A. M., Fatyol, K., Blakely, B. T., and Blau, H. M. (1998) Tetracycline-regulatable factors with distinct dimerization domains allow reversible growth inhibition by p16. *Nat Genet* **20**, 389-393.
- ROWE, W. P., HUEBNER, R. J., GILMORE, L. K., PARROTT, R. H., and WARD, T. G. (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. *Proc Soc Exp Biol Med* **84**, 570-573.
- Rubinchik, S., Wang, D., Yu, H., Fan, F., Luo, M., Norris, J. S., and Dong, J. Y. (2001) A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. *Mol Ther* **4**, 416-426.
- Rubinchik, S., Woraratanadharm, J., Yu, H., and Dong, J. Y. (2005) New complex Ad vectors incorporating both rtTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo. *Gene Ther* **12**, 504-511.
- Rubinchik, S., Yu, H., Woraratanadharm, J., Voelkel-Johnson, C., Norris, J. S., and Dong, J. Y. (2003) Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. *Cancer Gene Ther* **10**, 814-822.
- Russell, W. C. (2000) Update on adenovirus and its vectors. *J Gen Virol* **81** Pt 11:2573-604, 2573-2604.
- Sadeghi, H. and Hitt, M. M. (2005) Transcriptionally targeted adenovirus vectors. *Curr Gene Ther* **5**, 411-427.
- Salucci, V., Scarito, A., Aurisicchio, L., Lamartina, S., Nicolaus, G., Giampaoli, S., Gonzalez-Paz, O., Toniatti, C., Bujard, H., Hillen, W., Ciliberto, G., and Palombo, F. (2002) Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2(s)-M2 tetracycline transactivator and repressor system. *Gene Ther* **9**, 1415-1421.
- Sandalon, Z., Gnatenko, D. V., Bahou, W. F., and Hearing, P. (2000) Adeno-associated virus (AAV) Rep protein enhances the generation of a recombinant mini-adenovirus (Ad) utilizing an Ad/AAV hybrid virus. *J Virol* **74**, 10381-10389.
- Saphire, A. C., Guan, T., Schirmer, E. C., Nemerow, G. R., and Gerace, L. (2000) Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70. *J Biol Chem* **275**, 4298-4304.

- Sassone-Corsi, P. and Borrelli, E. (1987) Promoter trans-activation of protooncogenes c-fos and c-myc, but not c-Ha-ras, by products of adenovirus early region 1A. *Proc Natl Acad Sci U S A* **84**, 6430-6433.
- Satyamoorthy, K., Bogenrieder, T., and Herlyn, M. (2001) No longer a molecular black box-- new clues to apoptosis and drug resistance in melanoma. *Trends Mol Med* **7**, 191-194.
- Savontaus, M. J., Sauter, B. V., Huang, T. G., and Woo, S. L. (2002) Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. *Gene Ther* **9**, 972-979.
- Schrewe, H., Thompson, J., Bona, M., Hefta, L. J., Maruya, A., Hassauer, M., Shively, J. E., von Kleist, S., and Zimmermann, W. (1990) Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. *Mol Cell Biol* **10**, 2738-2748.
- Shaw, A. R. and Ziff, E. B. (1980) Transcripts from the adenovirus-2 major late promoter yield a single early family of 3' coterminal mRNAs and five late families. *Cell* **22**, 905-916.
- Shenk T. (1996) Adenoviridae: The viruses and their replication. In: *Fields Virology*, pp. 2111-2148. Eds Fields BN, Knipe DM, Howley PM. Lippincott-Raven: Philadelphia, New York.
- Shinoura, N., Yamamoto, N., Asai, A., Kirino, T., and Hamada, H. (2000) Adenovirus-mediated transfer of Fas ligand gene augments radiation-induced apoptosis in U-373MG glioma cells. *Jpn J Cancer Res* **91**, 1044-1050.
- Sipo, I., Hurtado, P. A., Wang, X., Eberle, J., Petersen, I., Weger, S., Poller, W., and Fechner, H. (2006) An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. *J Mol Med* **84**, 215-225.
- Srour, M. A., Fechner, H., Wang, X., Siemetzki, U., Albert, T., Oldenburg, J., Hanfland, P., Poller, W., Brackmann, H. H., and Schwaab, R. (2003) Regulation of human factor IX expression using doxycycline-inducible gene expression system. *Thromb Haemost* **90**, 398-405.
- Staba, M. J., Mauceri, H. J., Kufe, D. W., Hallahan, D. E., and Weichselbaum, R. R. (1998) Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. *Gene Ther* **5**, 293-300.
- Steenbergh, P. H., Maat, J., van Ormondt, H., and Sussenbach, J. S. (1977) The nucleotide sequence at the termini of adenovirus type 5 DNA. *Nucleic Acids Res* **4**, 4371-4389.
- Steinwaerder, D. S. and Lieber, A. (2000) Insulation from viral transcriptional regulatory elements improves inducible transgene expression from adenovirus vectors in vitro and in vivo. *Gene Ther* **7**, 556-567.
- Stewart, P. L., Burnett, R. M., Cyrklaff, M., and Fuller, S. D. (1991) Image reconstruction reveals the complex molecular organization of adenovirus. *Cell* **67**, 145-154.

- Strater, J., Walczak, H., Hasel, C., Melzner, I., Leithauser, F., and Moller, P. (2001) CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. *Cell Death Differ* **8**, 273-278.
- Sudarshan, S., Holman, D. H., Hyer, M. L., Voelkel-Johnson, C., Dong, J. Y., and Norris, J. S. (2005) In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. *Cancer Gene Ther* **12**, 12-18.
- Takahashi, M., Sato, T., Sagawa, T., Lu, Y., Sato, Y., Iyama, S., Yamada, Y., Fukaura, J., Takahashi, S., Miyanishi, K., Yamashita, T., Sasaki, K., Kogawa, K., Hamada, H., Kato, J., and Niitsu, Y. (2002) E1B-55K-Deleted Adenovirus Expressing E1A-13S by AFP-Enhancer/Promoter Is Capable of Highly Specific Replication in AFP-Producing Hepatocellular Carcinoma and Eradication of Established Tumor. *Mol Ther* **5**, 627-634.
- Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M., and Inoue, M. (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. *Cancer Res* **59**, 551-557.
- Takeuchi, M., Shichinohe, T., Senmaru, N., Miyamoto, M., Fujita, H., Takimoto, M., Kondo, S., Katoh, H., and Kuzumaki, N. (2000) The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice. *Gene Ther* **7**, 518-526.
- Tan, B. T., Wu, L., and Berk, A. J. (1999) An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. *J Virol* **73**, 7582-7589.
- Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. (1995) Expression of the functional soluble form of human fas ligand in activated lymphocytes. *EMBO J* **14**, 1129-1135.
- Teitz, T., Wei, T., Valentine, M. B., Vanin, E. F., Grenet, J., Valentine, V. A., Behm, F. G., Look, A. T., Lahti, J. M., and Kidd, V. J. (2000) Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. *Nat Med* **6**, 529-535.
- Thornberry, N. A. and Lazebnik, Y. (1998) Caspases: enemies within. *Science* **281**, 1312-1316.
- Tollefson, A. E., Hermiston, T. W., Lichtenstein, D. L., Colle, C. F., Tripp, R. A., Dimitrov, T., Toth, K., Wells, C. E., Doherty, P. C., and Wold, W. S. (1998) Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. *Nature* **392**, 726-730.
- Tomko, R. P., Xu, R., and Philipson, L. (1997) HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci U S A* **94**, 3352-3356.
- Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. M., and Krammer, P. H. (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. *Science* **245**, 301-305.

- TRENTIN, J. J., YABE, Y., and TAYLOR, G. (1962) The quest for human cancer viruses. *Science* **137**, 835-841.
- Tribouley, C., Lutz, P., Staub, A., and Kedinger, C. (1994) The product of the adenovirus intermediate gene IVa2 is a transcriptional activator of the major late promoter. *J Virol* **68**, 4450-4457.
- Tschopp, J., Irmiler, M., and Thome, M. (1998) Inhibition of fas death signals by FLIPs. *Curr Opin Immunol* **10**, 552-558.
- Unsinger, J., Kroger, A., Hauser, H., and Wirth, D. (2001) Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes. *Mol Ther* **4**, 484-489.
- Urlinger, S., Baron, U., Thellmann, M., Hasan, M. T., Bujard, H., and Hillen, W. (2000) Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. *Proc Natl Acad Sci U S A* **97**, 7963-7968.
- van Oostrum, J. and Burnett, R. M. (1985) Molecular composition of the adenovirus type 2 virion. *J Virol* **56**, 439-448.
- Viard-Leveugle, I., Veyrenc, S., French, L. E., Brambilla, C., and Brambilla, E. (2003) Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. *J Pathol* **201**, 268-277.
- Vile, R. G. (1994) Tumor-specific gene expression. *Semin Cancer Biol* **5**, 429-436.
- Vile, R. G. and Hart, I. R. (1993) In vitro and in vivo targeting of gene expression to melanoma cells. *Cancer Res* **53**, 962-967.
- Viswalingam, N. D. (1993) Adenovirus keratoconjunctivitis: an enigma. *Eye* **7**, 5-7.
- Vlodavsky, I., Friedmann, Y., Elkin, M., Aingorn, H., Atzmon, R., Ishai-Michaeli, R., Bitan, M., Pappo, O., Peretz, T., Michal, I., Spector, L., and Pecker, I. (1999) Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. *Nat Med* **5**, 793-802.
- Wadell, G., Allard, A., Johansson, M., Svensson, L., and Uhnö, I. (1987) Enteric adenoviruses. *Ciba Found Symp* **128**, 63-91.
- Wadell, G., Hammarskjöld, M. L., Winberg, G., Varsanyi, T. M., and Sundell, G. (1980) Genetic variability of adenoviruses. *Ann N Y Acad Sci* **354**, 16-42.
- Wallace, R. B., Shaffer, J., Murphy, R. F., Bonner, J., Hirose, T., and Itakura, K. (1979) Hybridization of synthetic oligodeoxyribonucleotides to phi chi 174 DNA: the effect of single base pair mismatch. *Nucleic Acids Res* **6**, 3543-3557.
- Walton, T., Wang, J. L., Ribas, A., Barsky, S. H., Economou, J., and Nguyen, M. (1998) Endothelium-specific expression of an E-selectin promoter recombinant adenoviral vector. *Anticancer Res* **18**, 1357-1360.

- Wang, Y., DeMayo, F. J., Tsai, S. Y., and O'Malley, B. W. (1997) Ligand-inducible and liver-specific target gene expression in transgenic mice. *Nat Biotechnol* **15**, 239-243.
- Webb, H. E. and Smith, C. E. (1970) Viruses in the treatment of cancer. *Lancet* **1**, 1206-1208.
- Weber, J. M., Dery, C. V., Mirza, M. A., and Horvath, J. (1985) Adenovirus DNA synthesis is coupled to virus assembly. *Virology* **140**, 351-359.
- Wei, S. J., Chao, Y., Shih, Y. L., Yang, D. M., Hung, Y. M., and Yang, W. K. (1999) Involvement of Fas (CD95/APO-1) and Fas ligand in apoptosis induced by ganciclovir treatment of tumor cells transduced with herpes simplex virus thymidine kinase. *Gene Ther* **6**, 420-431.
- Weiden, M. D. and Ginsberg, H. S. (1994) Deletion of the E4 region of the genome produces adenovirus DNA concatemers. *Proc Natl Acad Sci U S A* **91**, 153-157.
- White, E. (1996) Life, death, and the pursuit of apoptosis. *Genes Dev* **10**, 1-15.
- Wirth, T., Kuhnel, F., and Kubicka, S. (2005) Telomerase-dependent gene therapy. *Curr Mol Med* **5**, 243-251.
- Wold, W. S. and Gooding, L. R. (1991) Region E3 of adenovirus: a cassette of genes involved in host immunosurveillance and virus-cell interactions. *Virology* **184**, 1-8.
- Xie, B., Tam, N. N., Tsao, S. W., and Wong, Y. C. (1999) Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 andflt-1) in hormone-induced mammary cancer in the Noble rat. *Br J Cancer* **81**, 1335-1343.
- Xu, Z. L., Mizuguchi, H., Mayumi, T., and Hayakawa, T. (2003) Regulated gene expression from adenovirus vectors: a systematic comparison of various inducible systems. *Gene* **309**, 145-151.
- Yamamoto, M., Alemany, R., Adachi, Y., Grizzle, W. E., and Curiel, D. T. (2001) Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. *Mol Ther* **3**, 385-394.
- Yang, L., Cao, Z., Yan, H., and Wood, W. C. (2003) Coexistence of high levels of apoptotic signaling and inhibitor of apoptosis proteins in human tumor cells: implication for cancer specific therapy. *Cancer Res* **63**, 6815-6824.
- Yao, F., Svensjo, T., Winkler, T., Lu, M., Eriksson, C., and Eriksson, E. (1998) Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. *Hum Gene Ther* **9**, 1939-1950.
- Yu, D. C., Chen, Y., Seng, M., Dilley, J., and Henderson, D. R. (1999a) The Addition of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 to Eliminate Distant Prostate Tumor Xenografts. *Cancer Res* **59**, 4200-4203.

- Yu, D. C., Sakamoto, G. T., and Henderson, D. R. (1999b) Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy. *Cancer Res* **59**, 1498-1504.
- Zabala, M., Wang, L., Hernandez-Alcoceba, R., Hillen, W., Qian, C., Prieto, J., and Kramer, M. G. (2004) Optimization of the Tet-on system to regulate interleukin 12 expression in the liver for the treatment of hepatic tumors. *Cancer Res* **64**, 2799-2804.
- Zhang, J., Ramesh, N., Chen, Y., Li, Y., Dilley, J., Working, P., and Yu, D. C. (2002a) Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel. *Cancer Res* **62**, 3743-3750.
- Zhang, L., Akbulut, H., Tang, Y., Peng, X., Pizzorno, G., Sapi, E., Manegold, S., and Deisseroth, A. (2002b) Adenoviral Vectors with E1A Regulated by Tumor-Specific Promoters Are Selectively Cytolytic for Breast Cancer and Melanoma. *Mol Ther* **6**, 386.
- Zhang, W. and Imperiale, M. J. (2000) Interaction of the adenovirus IVa2 protein with viral packaging sequences. *J Virol* **74**, 2687-2693.
- Zhang, W., Low, J. A., Christensen, J. B., and Imperiale, M. J. (2001) Role for the adenovirus IVa2 protein in packaging of viral DNA. *J Virol* **75**, 10446-10454.
- Zheng, C., Baum, B. J., Iadarola, M. J., and O'Connell, B. C. (2000) Genomic integration and gene expression by a modified adenoviral vector. *Nat Biotechnol* **18**, 176-180.
- Zhu, J., Gao, B., Zhao, J., and Balmain, A. (2000) Targeting gene expression to tumor cells with loss of wild-type p53 function. *Cancer Gene Ther* **7**, 4-12.